Die Suchmaschine für Unternehmensdaten in Europa
EU-Förderung (7.518.062 €): Next generation toolbox for greener pharmaceuticals design & manufacturing towards reduced environmental impact Hor01.06.2022 EU-Rahmenprogramm für Forschung und Innovation "Horizont"
Auf einen Blick
Text
Next generation toolbox for greener pharmaceuticals design & manufacturing towards reduced environmental impact
Pharmaceuticals have undoubtably made our world a better place, ensuring longer and healthier lives. However, pharmaceuticals and their active metabolites are rapidly emerging environmental toxicants. It is thus critical that we fully understand, and mitigate where nec-essary, the environmental impact resulting from their production, use and disposal. In this direction, ENVIROMED addresses two aspects of the environmental impact of pharmaceuticals, a) impact of the processes in manufacturing the compound, and b) impact of the compound itself, during its lifecycle. The project narrows the knowledge gap when it comes to the effect of pharmaceutical compounds, and their derivatives, in the environment as it enables the better understanding the environmental impact of such compounds, throughout their lifecycle. It aims to offer (via extensive monitoring campaigns & scientific studies) information regarding occurrence of pharmaceuticals in the environment, their persistence, environmental fate, and toxicity (via in-vitro & in-vivo models) as well as application of in-silico methods to provide information about the basic risk management and fate prediction in the environment. Brief ideas about toxicity endpoints, available ecotoxicity databases, and expert systems employed for rapid toxicity predictions of ecotoxicity of pharmaceuticals will also be taken into account, in order to have a comprehensive approach to pharmaceuticals' Lifecycle Assessment (LCA). Moreover, the project aims at developing a set of technologies that enable greener and overall, more efficient pharmaceuticals production, which include: a) Green-by-design in-silico drug development; b) Novel sensing to allow reduction of rinsing chemicals and cycles; c) a robust Continuous Biomanufacturing line (CBM), which makes use of AI-enabled process optimisation and prediction, using data assimilation based on chemical sensing and energy disaggregation/monitoring. Training activities and a robust exploitation
Geförderte Unternehmen:
| Firmenname | Förderungssumme |
| Agilent Technologies LDA UK Ltd. | ? |
| Cloudpharm Private Company | 533.375 € |
| Consiglio Nazionale Delle Ricerche | 552.625 € |
| CY.R.I.C Cyprus Research and Innovation Center Ltd. | 365.000 € |
| Etaireia Ydreyseos Kai Apochetefseos Proteyoysis Anonimi Etaireia | 312.375 € |
| Ethnicon Metsovion Polytechnion | 380.000 € |
| HORIBA EUROPE GmbH | 367.500 € |
| Innovation in Research & Engineering Solutions | 378.750 € |
| Mitera Idiotiki Geniki, Maieytiki,Gynaikologiki Kai Paidiatriki Kliniki ΑΕ | 408.125 € |
| Novo Nordisk A/S | 424.250 € |
| Pfizer Ireland Pharmaceuticals | 15.000,00 € |
| Plegma Labs Technologikes Lyseis Anonymos Etairia | 271.250 € |
| Research Center FOR NON Destructive Testing GmbH | 488.250 € |
| RISA SICHERHEITSANALYSEN GmbH | 902.500 € |
| Technische Universitaet Wien | 1.155.937 € |
| UAB Metis Baltic | 288.125 € |
| UNIVERSITAET ULM | 675.000 € |
Quelle: https://cordis.europa.eu/project/id/101057844
Diese Bekanntmachung wurde von Englisch nach Deutsch übersetzt. Die Bekanntmachung bezieht sich auf einen vergangenen Zeitpunkt, und spiegelt nicht notwendigerweise den heutigen Stand wider. Der aktuelle Stand wird auf folgender Seite wiedergegeben: Agilent Technologies LDA UK Ltd., Cheadle, Großbritannien.
Die Visualisierungen zu "Agilent Technologies LDA UK Ltd. - EU-Förderung (7.518.062 €): Next generation toolbox for greener pharmaceuticals design & manufacturing towards reduced environmental impact"
werden von
North Data
zur Weiterverwendung unter einer
Creative Commons Lizenz
zur Verfügung gestellt.
